Information, support and friendship
AMEND, AMEND USA, AMEND Australia and AMEND New Zealand are all run by patients, for patients, to inform and support anyone affected by Multiple Endocrine Neoplasia (MEN) types 1, 2 and 3 and associated endocrine syndromes and tumours.
We are here to break the isolation so often felt by those with these rare diseases, and we would be delighted to welcome you into our 'family'.
The aim of our website is to direct you as quickly as possible to our support services and to information you can trust on MEN1, MEN2, MEN3, MTC (medullary thyroid cancer), FMTC (familial medullary thyroid cancer), adrenal gland tumours (phaeochromocytomas), parathyroid hyperplasia, paragangliomas, FIPA (familial isolated pituitary adenoma) and SDHx (succinate dehydrogenase) disorders.
MEN patient perspective films
Latest Newsletter Available
AMEND's latest newsletter (Issue 48) is now available for our members to read.
This issue contains information on NHS England's Cancer Drugs Fund provision for certain MEN tumours, reports from two AMEND-funded researchers on their projects, AMEND's Counselling Service Development plans, AMEND USA fundraising and information events, and information and a booking form for our 2015 Patient Information Day in Leeds on 9th May. Of course, as usual there is also much, much more!
Please note that to view the latest newsletter, you must be a registered member of AMEND and will need to log in. Membership is free - click here to become a member.
AMEND 2015 Research Fund
AMEND's total Research Award Fund for 2015 is £50,000.
£40,000 of this is specifically for research projects directed to the study of medullary thyroid cancer (MTC).
The remaining £10,000 makes up our usual annual award for studies into endocrine tumours within the context of multiple endocrine neoplasia (MEN).
The AMEND Research Fund is now open and inviting good quality applications.
Page 1 of 17